Loading
訊聯基因 Stock: price and insider trades · Taiwan
TW·Mcap NT$1.1B
訊聯基因: what insiders have been doing
We have very little insider data for 訊聯基因 so far: the most recent filing dates from 13 May 2026. With so few records, no pattern can be drawn yet. Every figure here comes from the filings published by TWSE / TPEx (MOPS) and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 17,587 of 26,169 companies
40.3
score / 100
Value30
Quality51
FCF yld-4.7%
Earn yld2.0%
EV/EBITDA21.4x
ROE3.7%
Gross mgn42%
Net mgn3.5%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
NT$40
Analyst consensus
Income statement
RevenueNT$603.1M
Gross profitNT$250.4M42% margin
EBITDANT$53.5M9% margin
Net incomeNT$21.4M2.9% margin
Valuation
PER (trailing)59.2x
P/Book2.2x
Beta0.33
Balance sheet & cash
Market capNT$1.1B
Total debtNT$80.1M
Free Cash Flow-NT$49.6M
Debt / Equity26%
Profitability & ownership
ROE3.7%
ROA0.1%
% insiders37.9%
% institutions0.0%
Last declaration on 13 May 2026
About 訊聯基因
訊聯基因 is a company listed on the XTAI market, specializing in genomics and biotechnology. It focuses on developing innovative solutions for health and personalized medicine.